WASHINGTON (AP) — Federal regulators are challenging patents on 20 brand name drugs, including the blockbuster weight-loss injection Ozempic, in the latest action by the Biden administration targeting industry practices that drive up pharmaceutical prices.
The Federal Trade Commission on Tuesday sent warning letters to 10 drugmakers, taking issue with patents on popular drugs for weight loss, diabetes, asthma and other reparatory conditions. The letters allege that certain patents filed by Novo Nordisk, GlaxoSmithKline, AstraZeneca and seven other companies are inaccurate or misleading.
Brand-name drugmakers use patents to protect their medicines and stave off cheaper, generic medicines. Most blockbuster drugs are protected by dozens of patents covering various ingredients, manufacturing processes and intellectual property. Generic drugmakers can only launch their own cheaper versions if the patents have expired or are successfully challenged in court.
Related articles:
Related suggestion:
Afternoon tea makes a comeback thanks to the snapNetflix fans are left STUNNED by the streaming site's 'most UNHINGED' show yetQueen Mary and King Frederik slammed for 'unprofessional' approach over the Easter long weekendShocking moment Oakland jewelry shop owner cowers in terror as gang of hammer16,000 SQ FT home in Montana goes on sale for just $10Seafood shocker: Warning shrimp and lobster contain dangerous levels of cancerThrough the palace keyhole... by those who were thereWoman is branded a 'bad person' after insisting pet owners should not take on 'lifeREVEALED: The top 35 fastestThierry Henry predicts Phil Foden's stunning goal in 3
2.5638s , 6491.078125 kb
Copyright © 2024 Powered by US challenges 'bogus' patents on Ozempic and other drugs in effort to spur competition ,Starry Scope news portal